VivoSeq
Other

Vomiting

47

Pipeline Programs↗

5

Active Trials↗

22

Companies Involved↗

Vomiting is a moderately active landscape with 47 programs across 22 companies. The most active players are Takeda, Dynogen Pharmaceuticals, Eastern Cooperative Oncology Group. 15 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1D

Dynogen Pharmaceuticals

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2S

Steriscience Pte

1 program

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical14

Divalproex Sodium

Teva

Fosaprepitant

Merck & Co.

Fentanyl

Cephalon

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Propofol

Fresenius Kabi Oncology Ltd.

Phase 11

TAK-951

Takeda

Phase 212

Vincristine Sulfate

Eastern Cooperative Oncology Group

Aprepitant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Doxorubicin

Pfizer

Mesna

Baxter Healthcare Corporation

Ifosfamide

Baxter Healthcare Corporation

Phase 35

Granisetron

Conrado Roberto Hoffmann Filho

Ramosetron

Astellas

Olanzapine

MODAG GmbH

Granisetron and Dexamethasone

Guangxi Medical University

Dexamethasone and Ondasetron

Instituto Materno Infantil Prof. Fernando Figueira

Approved15

Palonosetron

Avyxa

Capsaicin

Averitas Pharma, Inc.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ondansetron

Novartis

Dexamethasone

Aspen Global Incorporated

Analysis

Trial Status

49

clinical trials

Completed30 · 61%
Unknown status6 · 12%
Terminated6 · 12%
Recruiting3 · 6%
Not yet recruiting2 · 4%
Withdrawn2 · 4%

Clinical Trials

Trial Activity

49 trials

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
Recruiting·—·Phase 4·NCT07217600·60 enrolled
Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy
Recruiting·UUmeå University·Phase 4·NCT03783182·100 enrolled
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Recruiting·—·Phase 3·NCT06588413·172 enrolled
Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy
Not yet recruiting·SShanghai Children's Medical Center·N/A·NCT06371014·200 enrolled
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Not yet recruiting·SShanghai Children's Medical Center·Phase 3·NCT07035821·100 enrolled
The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain
Completed·UUniversity of Colorado, Denver·Phase 4·NCT04563494·127 enrolled
Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS
Completed·MMansoura University·Phase 4·NCT03932578·60 enrolled
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
Completed·CChinese Academy of Medical Sciences·Phase 2·NCT03572829·44 enrolled
Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01739985·322 enrolled
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
Completed·HHamad Medical Corporation·Phase 1·NCT02473887·40 enrolled
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT00293384·40 enrolled
Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy
Completed·PPrince of Songkla University·Phase 2·NCT01543945·340 enrolled
Topical Capsaicin for Cyclical Vomiting
Completed·HHenry Ford Health System·Phase 2·NCT03223350·30 enrolled
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
Completed·Astellas logoAstellas·Phase 3·NCT00272285·287 enrolled
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 3·NCT04535141·91 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)